Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue

Inclusion Criteria: * Diagnosis of Ulcerative Colitis or Crohn's Disease established at least 6 months prior to Day 1 by endoscopy and/or imaging * At least 6 months of clinical remission (Harvey Bradshaw Index ≤5; Mayo clinical score ≤ 2) * Therapy with mesalamine, immunosuppressors or anti-tumor necrosis factor alpha (TNFα) at stable doses for at least 3 months prior enrollment; steroids are not permitted from 6 months prior baseline * Chronic fatigue symptoms (MFI-20\>13) * Iron deficiency: ferritin \< 100 microg/l or \< 300 microg/l in case of Transferrin-Iron Saturation Percentage (TSAT) \<20% * Women of childbearing potential must have a negative serum pregnancy test before enrollment. * Able and willing to provide written informed consent Exclusion Criteria: * Known hypersensibility to active principle or excipients * Pregnant or lactating women * Clinically active IBD (Harvey Bradshaw Index \>6; Mayo clinical score \>3 or C-Reactive Protein \>2.5 mg/L * Renal failure (eGFR\<60) * History of adrenal insufficiency * History of autoimmune diseases * History of malignancies * Depression * Any current or recent signs or symptoms of viral infectious diseases * Recent psycho-traumatic events * Hemoglobin levels \< 12.5 g/dl (men) or \<11.5 g/dL (women)